Kratom, Once Again
Does this remind anyone of the 'grass roots' movement that arose to lobby Congress for reduced restriction on long-term opioid prescribing for chronic pain patients?
Select Page
Alcohol may be the oldest. New ones are being invented every day. There are thousands, and keeping track of what they are and what they do isn’t easy.
by C. Scott McMillin | Mar 18, 2024 | Addictive Substances | 0 |
Does this remind anyone of the 'grass roots' movement that arose to lobby Congress for reduced restriction on long-term opioid prescribing for chronic pain patients?
by C. Scott McMillin | Feb 8, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Jan 29, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Jan 25, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Jan 18, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Jan 8, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Dec 21, 2023 | Addictive Substances | 0 |
What seemed so incredibly important while under the influence had lost a lot of its charm when sober.
Read Moreby C. Scott McMillin | Dec 14, 2023 | Addictive Substances, Public Policy | 0 |
It’s just good business. The stuff is virtually unregulated, far more affordable to make and distribute, and quite profitable, especially where conservative legislators are unlikely to legalize marijuana anytime soon.
Read Moreby C. Scott McMillin | Dec 11, 2023 | Addictive Substances | 0 |
P2P has two advantages over traditional ephedrine-based meth, from the perspective of a cartel. First, as a true synthetic, there’s no natural upper limit on how much can be produced. Second, the P2P form is extremely cheap, both to make and sell.
Read Moreby C. Scott McMillin | Dec 4, 2023 | Addictive Substances | 0 |
Articles such as this remind me of the early days of tobacco marketing, when cigarettes were promoted as good for your health.
Read Moreby C. Scott McMillin | Nov 27, 2023 | Addictive Substances | 0 |
Translation: the absence of adequate masking would presumably explain why ketamine appeared superior – due to an error in the study design.
Read Moreby C. Scott McMillin | Nov 9, 2023 | Addictive Substances | 0 |
Once again based on experience, I’m confident that many of the folks who will try psilocybin in future, because of all the favorable publicity, will fall into those ‘excluded’ categories.
Read Moreby C. Scott McMillin | Oct 30, 2023 | Addictive Substances | 0 |
Unfortunately, adulterating fentanyl with xylazine makes naloxone substantially less effective in terms of reviving an overdose victim.
Read Moreby C. Scott McMillin | Oct 19, 2023 | Addictive Substances | 0 |
And if there were damage, it’d be our brains that were affected, right? The very organ we’re asking now to evaluate its own functioning. It’s not a happy thought.
Read Moreby C. Scott McMillin | Oct 9, 2023 | Addictive Substances | 0 |
Bad experiences are not exactly rare. Why isn’t this being discussed in the media?
Read Moreby C. Scott McMillin | Sep 21, 2023 | Addictive Substances | 0 |
Yes, they’re effective — for a week or two. After that, most of their effectiveness has eroded. If someone is still taking them on a daily basis, it’s probably an indication of growing dependence
Read Moreby C. Scott McMillin | Sep 14, 2023 | Addictive Substances | 0 |
All that free positive publicity has surely been a great help to the emerging psychedelic industry and the elements in the financial community who are rushing to exploit it.
Read Moreby C. Scott McMillin | Aug 31, 2023 | Addictive Substances | 0 |
As many as fifty of these NPS designer drugs have been found to date. That sounds like a lot until we realize the potential for hundreds more to appear in future.
Read More